Percutaneous Transluminal Coronary Angioplasty (PTCA) Products: A Global Strategic Business Report
San Jose, CA (PRWEB) October 06, 2011
Follow us on LinkedIn - Coronary Heart Disease, also known as the Coronary Artery Disease, is presently the leading cause of death worldwide. The share of Coronary Heart Disease in terms of the total number of deaths is expected to reach 15% by the year 2030. One of the key causes of Coronary Heart Disease, obesity, is increasing rapidly worldwide, with around a billion people currently suffering from the condition globally. However, awareness of CHD is also increasing globally. As a result, demand for percutaneous procedures, such as angioplasty used in treating the condition, is expected to increase in the ensuing years, as incidence and prevalence of the condition rises. Coronary angioplasty and Coronary Artery Bypass Graft (CABG) represent the two major forms of revascularization procedures, which received much attention over the recent decades, and have revolutionized the heart disease treatment arena worldwide. However, significant regional disparities exist in terms of the adoption of these procedures. Thus far, the US remains the largest market for angioplasty as well as CABG procedures among the OECD countries in terms of per capita.
Angioplasty gained significant popularity over bypass surgery during the past decade among most major markets worldwide, emerging as a most preferred revascularization procedure. However, angioplasty is not considered a complete substitution to bypass surgery in all cases, specifically in multiple vessel obstructions, where bypass surgery continues to remain the best and the most preferred procedure. Presently, about 3.0 million angioplasty procedures are performed each year worldwide with the US alone accounting for almost a million of these procedures.
Minimally invasive treatments are capturing increased interest from the patients as it entails minimum involvement in terms of time and cost. Angioplasty treatment, introduced initially as a procedure involving dilation of arteries using a balloon, has now expanded to include various advanced products, such as drug-coated stents and drug-eluting balloons. Development of novel technologies, such as Drug-Eluting Balloons (DEBs), are offering hope to patients by circumventing concerns that have been raised against drug-eluting stents in the recent years. As demand for these procedures increase, demand for products used in these procedures, such as balloon catheters, guide wires, and guiding catheters, is also expected to increase. Today’s angioplasty procedures involve the use of balloon catheters, which are inflated to support widening of the vessel.
The US represents the largest regional market worldwide, as stated by the new market research report on Percutaneous Transluminal Coronary Angioplasty (PTCA) Products. Europe trails behind the US market. However, growth in the market would be led by Asia-Pacific, which is projected to be the fastest growing regional market during the analysis period. Asia-Pacific market for PTCA products is forecast to post a compounded annual growth rate of about 4.2% during the analysis period. Segment wise, Balloon Catheters constitute the largest segment, while Guide Wires represents the fastest growing market segment.
Global market for Percutaneous Transluminal Coronary Angioplasty (PTCA) products witnessed subdued growth in the wake of the global economic downturn. However, despite significant pressure on sales, the sector managed to emerge out of the recession largely unscathed, as year-on-year growth during the recession-struck period from 2008 to 2010 suffered marginal slowdown. Regionally, the US, Canada, and Rest of World markets witnessed the lowest growth rate on an annual basis during the period 2008-2010. On the other hand, fastest rebounds were witnessed in Asia-Pacific and Latin America, which registered increases in annual growth as early as in 2010. However, beginning 2011, the market is expected to witness rapid recovery, and post increases in terms of annual growth.
Drug-Eluting Balloon (DEB) is the latest technological advancement in the area of intravascular procedures for treating stenosis of arterial vessels. The technology promises to be a major alternative to existing technologies such as stents, especially in applications such as the treatment of peripheral arterial disease, with lesser prospects in coronary applications. Since the debut of the concept, drug-eluting balloons drew significant interest from interventional radiologists and cardiologists, who were scouting for means and methods to minimize lesion restenosis rates and to enhance procedural success. Although only a few products have received approval thus far, many more are expected to emerge in the market given the number of products that are being evaluated in the clinical and pre-clinical development stages. Several drug-eluting balloons have been sold across major markets such as Asia and Europe, while the technology is used sporadically in the US.
Major players profiled in the report include Abbott Vascular, Boston Scientific Corp., Cordis Corp., C. R. Bard Inc., Goodman Co. Ltd., Medtronic Inc., Terumo Corp., among others.
The report titled “Percutaneous Transluminal Coronary Angioplasty (PTCA) Products: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the PTCA products markets, current market trends, key growth drivers, recent product launches, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Percutaneous Transluminal Coronary Angioplasty (PTCA) Products market for the years 2009 through 2017 for the following geographic markets - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. The report analyzes the market by the following segments –PTCA Balloon Catheters, PTCA Guiding Catheters, and PTCA Guide Wires. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Percutaneous_Transluminal_Coronary_Angioplasty_PTCA_Products_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/